



16 42
ABX-PF2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Larry Ronald Helms
Group Art Unit : 1642
Applicants : Bruce D. Cohen et al.
Application No. : 10/038,591
Confirmation No. : 1445
Filed : January 4, 2002
For : ANTIBODIES TO INSULIN-LIKE GROWTH
FACTOR I RECEPTOR

New York, New York
August 30, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

In accordance with 37 C.F.R. § 1.97, this Statement is accompanied by the fee as set forth in 37 C.F.R. § 1.17(p).

The Director is hereby authorized to charge payment of any additional fees required in connection with the accompanying Information Disclosure Statement, or

credit any overpayment, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

Jane T. Gunnison


Jane T. Gunnison (Reg. No. 38,479)
Attorney for Applicants
FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

August 30, 2008

Claire J. Schmitz-von Goodman

[Signature]
Signature of Person Signing



ABX-PF2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Larry Ronald Helms
Group Art Unit : 1642
Applicants : Bruce D. Cohen et al.
Application No. : 10/038,591
Confirmation No. : 1445
Filed : January 4, 2002
For : ANTIBODIES TO INSULIN-LIKE GROWTH
FACTOR I RECEPTOR

New York, New York
August 30, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants hereby make of record the references listed below. Copies of these references are enclosed.¹

UNITED STATES PATENTS

United States Patent 6,146,629 issued to Dagan et al. on November 14, 2000.

¹ For the Examiner's convenience, applicants have also enclosed a completed Form PTO-1449, listing these documents.

FOREIGN PATENTS

PCT Patent Application WO 96/33735, (Kucherlapati, R., et al.) published October 31, 1996.
PCT Patent Application WO 00/56772, (Salfeld, J.G., et al.) published September 28, 2000.

OTHER REFERENCES

Li, S.-L. et al., "Single-chain Antibodies Against Human Insulin-like Growth Factor I Receptor: Expression, Purification and Effect on Tumor Growth," *Cancer Immunology and Immunotherapy*, 49:243-252 (2000).

Hermanto, U. et al., "Inhibition of Mitogen-activated Protein Kinase Kinase Selectively Inhibits Cell Proliferation in Human Breast Cancer Cells Displaying Enhanced Insulin-like Growth Factor I-mediated Mitogen-activated Protein Kinase Activation," *Cell Growth & Differentiation*, 11:655-664 (2000).

REMARKS

It is respectfully requested that the Examiner (1) fully consider the enclosed references during the examination of this application; (2) initial the enclosed Form PTO-1449 in the appropriate places to indicate that the references have been considered; and return a copy of the initialed Form to the undersigned in accordance with MPEP § 609 and § 2001.06(b).

Respectfully submitted,

Jane T. Gunnison


Jane T. Gunnison (Reg. No. 38,479)
Attorney for Patents
FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1105
Tel.: (212) 596-9000
Fax: (212) 596-9090

I hereby certify that this
Correspondence is being
deposited with the U.S.
Postal Service as First
Class Mail in an envelope
Addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

August 30, 2004
Claire J. Salvo-van Goodman

[Signature]
Signature of Person Signing

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ABX-PF2APPLN. NO.
10/038,591INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Bruce D. Cohen et al.CONFIRMATION
NO. 1445FILING DATE
January 4, 2002GROUP
1642

UNITED STATES. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,146,629	11/14/2000	Dagan, et al.	424	149.1	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 96/33735	10/31/1996	PCT	A61K	39/00		X
	WO 00/56772	09/28/2000	PCT	C07K	16/24		X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Li, S.-L. et al., "Single-chain Antibodies Against Human Insulin-like Growth Factor I Receptor: Expression, Purification and Effect on Tumor Growth," <i>Cancer Immunology and Immunotherapy</i> , 49:243-252 (2000).
	Hermanto, U. et al., "Inhibition of Mitogen-activated Protein Kinase Kinase Selectively Inhibits Cell Proliferation in Human Breast Cancer Cells Displaying Enhanced Insulin-like Growth Factor I-mediated Mitogen-activated Protein Kinase Activation," <i>Cell Growth & Differentiation</i> , 11:655-664 (2000).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.